A collaboration between Biofabri, a non-profit organisation, and academics from South Africa are pressing ahead with clinical development of a novel tuberculosis vaccine candidate known as
Novo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to discover and develop RNA-blocking therapies for diseases such as NASH and ty
